Unique ID issued by UMIN | UMIN000002416 |
---|---|
Receipt number | R000002961 |
Scientific Title | Efficacy of intra-hepatic arterial chemotherapy (IHAC) vs. sorafenib on advanced hepatocellular carcinoma; a prospective cohort study (ISHCC-cohort) |
Date of disclosure of the study information | 2009/09/01 |
Last modified on | 2013/09/02 08:55:44 |
Efficacy of intra-hepatic arterial chemotherapy (IHAC) vs. sorafenib on advanced hepatocellular carcinoma; a prospective cohort study (ISHCC-cohort)
Intra-hepatic arterial chemotherapy (IHAC) vs. sorafenib for advanced hepatocellular carcinoma; a prospective cohort study (ISHCC-cohort)
Efficacy of intra-hepatic arterial chemotherapy (IHAC) vs. sorafenib on advanced hepatocellular carcinoma; a prospective cohort study (ISHCC-cohort)
Intra-hepatic arterial chemotherapy (IHAC) vs. sorafenib for advanced hepatocellular carcinoma; a prospective cohort study (ISHCC-cohort)
Japan |
hepatocellular carcinoma
Hepato-biliary-pancreatic medicine |
Malignancy
NO
To evaluate the efficacy of intra-hepatic arterial infusion chemotherapy and sorafenib in advanced hepatocellular carcinoma (multiple and/or vascular invasion)
Efficacy
Confirmatory
Pragmatic
Phase III
Overall survival
Progression free survival
Response rate
Tumor control rate
Adverse events
Interventional
Parallel
Non-randomized
Open -no one is blinded
Active
2
Treatment
Medicine |
A: Sorafenib
B: intra-hepatic arterial chemotherapy
Not applicable |
Not applicable |
Male and Female
1) hepatocellular carcinoma confirmed by dynamic CT or dynamic MRI, or histologically confirmed hepatocellular carcinoma
2) no indication for transplantation, surgical resection, local ablation or transcatheter arterial embolization.
3) Child-Pugh A
4) >=20 years old
5) ECOG Performance Status 0-2
6) oral intake is possible
7) no extrahepatic lesion,
8) more than one measurable disease
9) Adequate baseline organ function:
neutrophil > 1,500/mm3, hemoglobin >=8.5g/dl, platelets > 75,000/mm3, serum bilirubin <2.0mg/dL, aspartate aminotransferase and alanine aminotransferase <=5 times of the institutional upper limit, serum creatinine <2.0mg/dL
10) written informed consent
11) life expectancy >=3 months
1) histrogically confirmed combined type hepatocellular carcinoma or sarcomatous change
2) previous therapy for hepatocellular carcinoma within 30 days
3) inadequate for administration of sorafenib, 5-FU, cisplatin or interferon
4) active double cancer
5) severe complication
6) refractory ascites of pleural effusion
7) inappropriate for entry onto this study in the judgment of the investigator
700
1st name | |
Middle name | |
Last name | Shuichi Kaneko |
Kanazawa University Hospital
Department of Gastroenterology
13-1 Takara-Machi, Kanazawa, Ishikawa
076-265-2233
1st name | |
Middle name | |
Last name | Tatsuya Yamashita |
Kanazawa University Hospital
Department of Gastroenterology
13-1 Takara-machi, Kanazawa, Ishikawa
076-265-2861
ytatsuya@m-kanazawa.jp
Kanazawa University Hospital
Ministry of Health, Labour and Welfare
Japan
NO
金沢大学附属病院(石川県)
愛媛大学附属病院(愛媛県)
鳥取大学附属病院(鳥取県)
千葉大学附属病院(千葉県)
山口大学附属病院(山口県)
大阪大学附属病院(大阪府)
杏林大学附属病院(東京都)
東北大学附属病院(宮城県)
昭和大学附属病院(東京都)
兵庫医科大学附属病院(兵庫県)
近畿大学附属病院(大阪府)
岐阜大学附属病院(岐阜県)
岡山大学附属病院(岡山県)
虎ノ門病院(東京都)
久留米大学附属病院(福岡県)
2009 | Year | 09 | Month | 01 | Day |
Unpublished
Terminated
2009 | Year | 08 | Month | 31 | Day |
2009 | Year | 10 | Month | 01 | Day |
2012 | Year | 09 | Month | 01 | Day |
2009 | Year | 08 | Month | 31 | Day |
2013 | Year | 09 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002961